Loading
Golidocitinib is Dizal's JAK1 inhibitor, approved in China in 2024 as the first JAK inhibitor for relapsed peripheral T-cell lymphoma, a cancer with few options after first-line chemotherapy.
Dizal Pharmaceutical's golidocitinib (DZD4205) was approved by the NMPA in June 2024 for relapsed or refractory peripheral T-cell lymphoma, on the JACKPOT8 trial in which about 44 percent of patients responded. It is the first JAK1-selective inhibitor approved for a cancer. A phase 3 trial testing it as maintenance after first-line therapy is registered.
Selectively inhibits Janus kinase 1, the signalling node that peripheral T-cell lymphoma cells use through the JAK-STAT pathway. Connects to JAK1.
1.Golidocitinib slips into a pocket on JAK1.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| CN | 2024 | Relapsed or refractory peripheral T-cell lymphoma |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Golidocitinib" OR ABSTRACT:"Golidocitinib" OR TITLE:"DZD4205" OR ABSTRACT:"DZD4205") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Golidocitinib, not a curated reading list.
Shares Dizal Pharmaceutical, Small-molecule kinase inhibitors and the tag pipeline.
Shares Dizal Pharmaceutical and the tag pipeline.
Shares Dizal Pharmaceutical and the tag pipeline.
Shares Dizal Pharmaceutical and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.